ZLZarnie Lwin

Zarnie Lwin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Zarnie Lwin has a total of 54 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study

    by Antonio González-Martín, Hyun Cheol Chung, Esma Saada-Bouzid, Eduardo Yanez, Helene Senellart, Philippe A. Cassier, Bristi Basu, Bradley R. Corr, Eugenia Girda, Corina Dutcus, et al.


  • Clinical Trials in the Brain Tumour Population: Challenges and Strategies for the Future

    by Hui Kong Gan, Bryan W. Day, Rosemary Harrup, Terrance G. Johns, Zarnie Lwin, Andrew Mark Scott, Hao-Wen Sim, Eng-Siew Koh

    Purpose of Review This review identifies challenges and barriers to successful development of drugs in neuro-oncology trials at the preclinical, clinical and translational stages that we believe has contributed to poor outcomes for patients over the last 30 years. Recent Findings Several key strategies have been proposed by leading groups to address these and improve patient outcomes. Better preclinical testing using more sophisticated and clinically relevant models is needed. A greater focus on assessing blood–brain barrier penetrance and targeting key biological processes such as tumour heterogeneity and immune response is vital. Adopting innovative trial designs permitting faster results and addressing key issues (including molecular heterogeneity and combinatorial approaches) is highly desirable. A stronger translational focus is also clearly needed. Summary Implementation of these strategies is already starting to occur. Maintaining and increasing these novel approaches will require coordinated efforts between clinicians, scientists, industry and funding/regulator bodies.


  • From survivorship to end-of-life discussions for brain tumor patients

    by Zarnie Lwin

    As we embrace 2021 with fresh hope and positivity, it is my great honor to represent ASNO and serve as Executive Editor of Neuro-Oncology Practice. I am deeply humbled to receive the baton from Prof Rakesh Jalali and will continue in his footsteps of dedication and strong commitment—striving to improve the journey of patients, families, and carers from every corner of the world. I feel privileged for the opportunity to serve with a distinguished Editorial team under the strong leadership of Prof Martin Taphoorn, together with Dr Terri Armstrong and Dr Patrick Roth.


  • Open Access

    Q-Cell Glioblastoma Resource: Proteomics Analysis Reveals Unique Cell-States Are Maintained in 3D Culture

    by Rochelle C. J. D’souza, Carolin Offenhäuser, Jasmin Straube, Ulrich Baumgartner, Anja Kordowski, Yuchen Li, Brett W. Stringer, Hamish Alexander, Zarnie Lwin, Po-Ling Inglis, et al.

    Glioblastoma (GBM) is a treatment-refractory central nervous system (CNS) tumour, and better therapies to treat this aggressive disease are urgently needed. Primary GBM models that represent the true disease state are essential to better understand disease biology and for accurate preclinical therapy assessment. We have previously presented a comprehensive transcriptome characterisation of a panel (n = 12) of primary GBM models (Q-Cell). We have now generated a systematic, quantitative, and deep proteome abundance atlas of the Q-Cell models grown in 3D culture, representing 6167 human proteins. A recent study has highlighted the degree of functional heterogeneity that coexists within individual GBM tumours, describing four cellular states (MES-like, NPC-like, OPC-like and AC-like). We performed comparative proteomic analysis, confirming a good representation of each of the four cell-states across the 13 models examined. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis identified upregulation of a number of GBM-associated cancer pathway proteins. Bioinformatics analysis, using the OncoKB database, identified a number of functional actionable targets that were either uniquely or ubiquitously expressed across the panel. This study provides an in-depth proteomic analysis of the GBM Q-Cell resource, which should prove a valuable functional dataset for future biological and preclinical investigations.


  • Open Access

    The Australian Medical Oncologist Workforce Survey: The profile and challenges of medical oncology

    by Zarnie Lwin, Alex Broom, David Sibbritt, Kay Francis, Christos S Karapetis, Deme Karikios, Rosemary Harrup


  • Open Access

    “It doesn’t exist…”: negotiating palliative care from a culturally and linguistically diverse patient and caregiver perspective

    by Emma Kirby, Zarnie Lwin, Katherine Kenny, Alex Broom, Holi Birman, Phillip Good

    The end of life represents a therapeutic context that acutely raises cultural and linguistic specificities, yet there is very little evidence illustrating the importance of such dynamics in shaping choices, trajectories and care practices. Culture and language interplay to offer considerable potential challenges to both patient and provider, with further work needed to explore patient and caregiver perspectives across cultures and linguistic groups, and provider perspectives. The objective of this study was to develop a critical, evidence-based understanding of the experiences of people from Culturally and Linguistically Diverse (CALD) backgrounds, and their caregivers, in a palliative care setting. A qualitative study, using semi-structured interviews to explore key experiences and perspectives of CALD patients and caregivers currently undergoing treatment under oncology or palliative care specialists in two Australian hospitals. Interviews were digitally audio recorded and transcribed in full. A thematic analysis was conducted utilising the framework approach. Sixteen patients and fourteen caregivers from a range of CALD backgrounds participated in semi-structured interviews. The research identified four prevalent themes among participants: (1) Terminology in the transition to palliative care; (2) Communication, culture and pain management; (3) (Not) Talking about death and dying; and, (4) Religious faith as a coping strategy: challenging the terminal diagnosis. CALD patients and caregivers’ experiences are multifaceted, particularly in negotiating linguistic difficulties, beliefs about treatment, and issues related to death and dying. Greater attention is needed to develop effective communication skills, recognise CALD patients’ particular cultural, linguistic and spiritual values and needs, and acknowledge the unique nature of each doctor-patient interaction.


  • Open Access

    Involvement of low- and middle-income countries in randomized controlled trial publications in oncology

    by Janice C Wong, Kimberly A Fernandes, Shubarna Amin, Zarnie Lwin, Monika K Krzyzanowska

    We describe trends in participation by investigators from low- and middle-income countries (LMCs) in publications describing oncology randomized control trials (RCTs) over a decade. We used Medline to identify RCTs published in English from 1998 to 2008 evaluating treatment in lung, breast, colorectal, stomach and liver cancers. Data on author affiliations, authorship roles, trial characteristics, funding and interventions were extracted from each article. Countries were stratified as low-, middle- or high-income using World Bank data. Interventions were categorized as requiring basic, limited, enhanced or maximal resources as per the Breast Health Global Initiative classification. Logistic regression was used to identify factors associated with authorship by investigators from LMCs. 454 publications were identified. Proportion of articles with at least one LMC author increased over time from 20% in 1998 to 29% in 2008 (p = 0.01), but almost all LMC authors were from middle-income countries. Proportion of articles with at least one LMC author was higher among articles that explicitly reported recruitment in at least one LMC vs those that did not (76% vs 13%). Among 87 articles (19%) that involved authors from LMCs, 17% had LMC authors as first or corresponding authors, and 67% evaluated interventions requiring enhanced or maximal resources. Factors associated with LMC authorship included industry funding (OR = 3.54, p = 0.0001), placebo comparator arm (OR = 2.57, p = 0.02) and palliative intent treatment (OR = 4.00, p = 0.0003). An increasing number of publications describing oncology RCTs involve authors from LMC countries but primarily in non-leadership roles in industry-funded trials.


  • Open Access

    Culturally and linguistically diverse patient participation in glioma research

    by Zarnie Lwin, Alexander Broom, Rasha Cosman, Ann Livingstone, Kate Sawkins, Phillip Good, Emma Kirby, Eng-Siew Koh, Elizabeth Hovey, on behalf of the COGNO CALD working group

    Marginal communities, such as culturally and linguistically diverse (CALD) patients, have significantly lower rates of recruitment, accrual, and retention in cancer clinical trials. A combination of language and cultural barriers means that trial participation from CALD communities remains at suboptimal levels, which in turn favors research findings that are biased towards therapeutic effects or toxicities within the context of non-CALD populations. Here we outline some key challenges and implications for CALD patient participation in glioma research in countries such as Australia, where English is the language of governance and health services implementation. We highlight multistakeholder interventions to improve both investigator recruitment and participation of CALD communities in future glioma research, particularly in this era when global migration has come of age. Enhancing research participation of CALD communities ensures not only wider understanding of genetic heterogeneity to improve glioma outcomes but also equity in access to care.